BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioNTech (Nasdaq: BNTX) outlined 2026 priorities at the 44th J.P. Morgan Healthcare Conference, emphasizing late-stage oncology acceleration, combination therapy programs, and disease-area focus across lung, breast, GI, GU and gynecologic cancers. The company expects 15 Phase 3 trials by year-end 2026 and seven late-stage data readouts in 2026, with at least 17 late-stage readouts by 2030+. BioNTech reported a strong balance sheet of €17.2 billion in cash and investments as of Dec 31, 2025, updated 2025 revenue guidance to €2.6–2.8 billion, and said it does not anticipate oncology product revenues in 2026. Presentation webcast scheduled for Jan 13, 2026.

Positive

• Cash and investments of €17.2 billion as of Dec 31, 2025
• 2025 revenue guidance raised to €2.6–2.8 billion
• 15 Phase 3 trials anticipated by year-end 2026
• Seven late-stage readouts expected in 2026
• At least 17 late-stage readouts expected by 2030+

Negative

• Company does not expect oncology product revenues in 2026
• Anticipates a modest decline in Comirnaty (COVID-19 vaccine) revenues in 2026
• Transition from multi-year contracts to private markets may pressure vaccine revenue

News Market Reaction

+2.33%

24 alerts

+2.33% News Effect

+$592M Valuation Impact

$26.00B Market Cap

0.7x Rel. Volume

On the day this news was published, BNTX gained 2.33%, reflecting a moderate positive market reaction. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $592M to the company's valuation, bringing the market cap to $26.00B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash & investments: €17.2 billion 2025 revenue guidance: €2.6–2.8 billion 2026 Phase 3 trials: 15 trials +5 more

8 metrics

Cash & investments €17.2 billion Cash, cash equivalents and security investments as of Dec 31, 2025

2025 revenue guidance €2.6–2.8 billion Increased 2025 revenue guidance (November 2025 update, reiterated here)

2026 Phase 3 trials 15 trials Anticipated number of Phase 3 oncology trials ongoing by end of 2026

2026 late-stage readouts 7 readouts Expected 2026 oncology late-stage data readouts

Phase 2/3 oncology trials More than 25 trials Current number of Phase 2 or 3 oncology trials ongoing

New Phase 3 initiations 6 trials Planned additional Phase 3 oncology trial initiations in 2026

2030+ late-stage readouts At least 17 readouts Expected late-stage/pivotal oncology data readouts by 2030+

Comirnaty outlook 2026 Modest revenue decline Expected 2026 COVID-19 vaccine revenues vs 2025

Market Reality Check

Price: $118.00 Vol: Volume 716,673 is below t...

low vol

$118.00 Last Close

Volume Volume 716,673 is below the 20-day average of 1,127,312, indicating no outsized trading interest before the update. low

Technical Price 99.85 is trading below the 200-day MA of 102.6, reflecting a subdued longer-term trend despite the strategic update.

Peers on Argus

BNTX gained 1.01% ahead of its strategy update, while key biotech peers showed m...

BNTX gained 1.01% ahead of its strategy update, while key biotech peers showed mixed moves: INSM -4.89%, GMAB +1.93%, INCY +0.78%, RPRX -0.94%, ONC +2.61%. This pattern points to stock-specific rather than sector-wide drivers.

Historical Context

5 past events · Latest: Dec 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 18	Acquisition completion	Positive	-0.1%	Completed CureVac acquisition to strengthen mRNA capabilities and oncology strategy.
Dec 09	Clinical data update	Positive	-1.5%	Interim Phase 2 pumitamig TNBC data showed encouraging efficacy and safety profile.
Dec 03	Acquisition progress	Positive	+0.7%	Minimum condition met in CureVac exchange offer with over 81% shares tendered.
Nov 26	Deal timeline update	Positive	+3.0%	Shared timing, exchange ratio, and vote support for CureVac exchange offer.
Nov 03	Earnings and pipeline	Positive	+0.0%	Q3 2025 results, higher revenue guidance, and positive pumitamig and COVID-19 updates.

Pattern Detected

Recent positive corporate, clinical, and earnings news has often seen modest or even negative immediate price reactions, suggesting tempered expectations around announcements.

Recent Company History

Over the last few months, BioNTech has focused on expanding its mRNA and oncology capabilities and solidifying its financial base. The company advanced an exchange offer and subsequent acquisition of CureVac, with key milestones on Dec 3, 2025 and closing on Dec 18, 2025. It reported Q3 2025 revenue of €1,518.9 million, raised 2025 revenue guidance to €2.6–2.8 billion, and highlighted encouraging Phase 2 pumitamig data. Today’s 2026 strategy and pipeline update builds directly on these acquisition, collaboration, and clinical developments.

Market Pulse Summary

This announcement outlines BioNTech’s transition toward a multi-product oncology company, backed by ...

Analysis

This announcement outlines BioNTech’s transition toward a multi-product oncology company, backed by €17.2 billion in cash and investments and 2025 revenue guidance of €2.6–2.8 billion. The company plans 15 Phase 3 trials and 7 late-stage readouts in 2026, plus at least 17 late-stage readouts by 2030+. Investors may track clinical milestones, regulatory steps such as a BLA submission for T-Pam, and the evolution of COVID-19 vaccine revenues versus growing oncology contributions.

Key Terms

antibody-drug conjugates, mRNA immunotherapies, phase 3 clinical trials, bla submission, +4 more

8 terms

antibody-drug conjugates medical

"pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

mRNA immunotherapies medical

"across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology"

mRNA immunotherapies are medicines that give cells short-lived instruction sheets (mRNA) to produce a specific protein that trains the immune system to recognize and attack a disease, such as cancer cells or pathogens. For investors, they matter because they represent a flexible, fast-to-design platform that can create high-value drugs but carry development, regulatory and manufacturing risks similar to other advanced biologics—like backing a promising new technology with scaling challenges.

phase 3 clinical trials medical

"and to have 15 Phase 3 clinical trials ongoing by year end"

Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.

bla submission regulatory

"Phase 3 Trial Initiations ... BLA Submission | T-Pam (HER2-ADC)"

A BLA submission is a company’s formal application to the U.S. Food and Drug Administration asking for permission to market a biologic drug or therapy. Think of it like applying for a permit to sell a complex medical product: the agency reviews safety, effectiveness, and manufacturing quality before deciding. For investors, a BLA filing signals a late-stage regulatory milestone that can reduce uncertainty and, if approved, unlock revenue and change a company’s valuation, while also carrying regulatory and timing risk.

ctdna medical

"Autogene cevumeran 3 | mRNA cancer immunotherapy | Phase 2 | Adj. ctDNA+ stage II"

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

pd-l1 medical

"BNT113 | mRNA cancer immunotherapy | Phase 3 | 1L HPV16+ PD-L1+ HNSCC"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

nsclc medical

"Pumitamig 1 | Immunomodulator | Phase 2 | 1L NSCLC"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

adc medical

"Trastuzumab pamirtecan (“T-Pam”) 4 | ADC | Single-arm Phase 2"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

AI-generated analysis. Not financial advice.

• 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies
• Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end
• Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product oncology company
• Financial strength with €17.2 billion in cash and cash equivalents plus security investments¹, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation
• Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference from 2:15 – 2:55 pm PT / 11:15 – 11:55 pm CET on Tuesday, January 13, 2026

Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an overview of expected near- to longer-term milestones, at the 44th Annual J.P. Morgan Healthcare Conference this week in San Francisco, California.

“We concluded 2025 with strong momentum, driven by our execution in research and development, partnerships, acquisitions, and our financial strength. We continued to advance our next wave of innovation, including the initiation of novel-novel combination trials. These achievements have successfully positioned us as a late-stage biopharmaceutical company,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “We see 2026 as a year when science translates into tangible results. We will report on a series of milestones, including readouts from late-stage trials and earlier trials evaluating novel-novel combinations, as well as new Phase 3 clinical trial initiations. If positive, they will help unlock our path towards multiple near- and mid-term product launch opportunities with the aim to benefit patients across cancer types.”

Ugur Sahin will present at the 44th Annual J.P. Morgan Healthcare Conference from 2:15 – 2:55 pm PT / 11:15 – 11:55 pm CET on Tuesday, January 13, 2026. The live webcast of the presentation can be accessed via the “Events & Presentations” page in the Investor Relations section of the Company's website. The slide deck will be available there after the presentation. A replay of the webcast will be archived on the Company’s website for 30 days following the conference.

Oncology Areas of Focus for 2026 
BioNTech will continue to execute its strategy in 2026 towards becoming a multi-product oncology company. Its diversified oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates (“ADCs”), and mRNA cancer immunotherapies. BioNTech is developing several assets with pan-tumor potential, including novel-novel combination approaches, with the aim of addressing the full continuum from early- to late-stage disease across selected tumor types.

1. Late-Stage Acceleration
BioNTech is focused on advancing its late-stage oncology pipeline towards potential launches. Within the past two years, the Company has more than doubled the number of Phase 2 and 3 oncology trials across key modalities with now more than 25 Phase 2 or 3 trials ongoing. In 2026, BioNTech plans to initiate six additional Phase 3 clinical trials, bringing the total number of anticipated Phase 3 clinical trials to 15, and expects seven late-stage data readouts. The clinical trials and resulting data will inform regulatory and launch plans.

2. Combination Therapy Momentum
BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026. These trials explore pumitamig (BNT327/BMS986545), which is being partnered with Bristol Myers Squibb (“BMS”), in combination with other investigational immunomodulators, ADCs, and mRNA cancer immunotherapies and will inform the dose selection and explore anti-tumor activity in multiple tumors for later-stage development.

3. From Modalities to Disease Area
With the maturation of the oncology pipeline, BioNTech will focus on specific disease areas across major cancer types, including lung, breast, gynecologic, gastrointestinal, and genitourinary cancers.

Expected 2026 Milestones

	Program	Modality	Trial Phase	Indication
Late-Stage Trial Readouts	Trastuzumab pamirtecan (“T-Pam”)4	ADC	Single-arm Phase 2	2L+ HER2-expressing endometrial cancer
			Phase 3	Chemo naïve HR+ HER2-low breast cancer
	Gotistobart2	Immunomodulator	Phase 3	2L+ sqNSCLC
			Phase 2	2L+ mCRPC
	BNT113	mRNA cancer immunotherapy	Phase 3	1L HPV16+ PD-L1+ HNSCC
	Pumitamig1	Immunomodulator	Phase 3 in China	1L TNBC
	Autogene cevumeran3	mRNA cancer immunotherapy	Phase 2	Adj. ctDNA+ stage II (high risk) / stage III CRC
Early-Stage Pumitamig & ADC Trial Readouts	Pumitamig1	Immunomodulator	Phase 2	1L NSCLC
			Phase 2	1L ES-SCLC
			Phase 2 in China	1L HCC
			Phase 2 in China	1L MSS-CRC
	Pumitamig1 + T-Pam (HER2-ADC)4	Immunomodulator + ADC	Phase 1/2	Breast cancer
	Pumitamig1 + BNT324/DB-1311 (B7H3-ADC)4		Phase 1/2	Advanced solid tumors
			Phase 2	NSCLC/SCLC
	Pumitamig1 + BNT325/DB-1305 (TROP2-ADC)4		Phase 2	TNBC
	Pumitamig1 + BNT326/YL202 (HER3-ADC)5		Phase 1/2	2L+ EGFRm NSCLC
	BNT324/DB-1311 (B7H3-ADC)4	ADC	Phase 1/2	2L+ mCRPC
Phase 3 Trial Initiations	Pumitamig1	Immunomodulator	Phase 3	1L MSS-CRC
			Phase 3	1L HER2- PD-L1+ gastric cancer
			Phase 3	1L HNSCC
	BNT324 /DB-1311 (B7H3-ADC)4	ADC	Phase 3	1L mCRPC
BLA Submission	T-Pam (HER2-ADC)4	ADC	-	2L+ HER2-expressing endometrial cancer

Partnered with: 1.  BMS; 2. OncoC4, Inc. (“OncoC4”); 3. Genentech, a member of the Roche Group; 4. Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"); 5. MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink").

Abbreviations: 1L = first line; 2L = second line; adj. = adjuvant; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; (sq) NSCLC = (squamous) non-small cell lung cancer; mCRPC = metastatic castration resistant prostate cancer; HPV16 = human papilloma virus 16; PD-L1 = programmed cell death protein ligand 1; HNSCC = head and neck squamous cell carcinoma; TNBC = triple-negative breast cancer; ctDNA = circulating tumor DNA; (MSS-)CRC = (microsatellite stable-) colorectal cancer; ES-SCLC = extensive-stage small cell lung cancer; HCC = hepatocellular carcinoma; EGFRm = mutated epidermal growth factor receptor

Overview of oncology data readouts expected by 2030+
BioNTech expects at least 17 late-stage data readouts, including from pivotal trials, by 2030+. The respective trials are set to inform multiple launch opportunities for BioNTech to become a multi-product oncology company by 2030. Potential further data readouts will be added with the evolution and maturation of the clinical pipeline.

Tumor type		Incidence1	Assets	Late-Stage/ Pivotal Trials	Expected Data Readouts2
Lung	1L NSCLC	400k	Pumitamig3	ROSETTA Lung-02	2029
			Gotistobart4	PRESERVE-003	2026
	1L ES-SCLC	80k	Pumitamig3	ROSETTA Lung-01	2028
Breast	1L TNBC – all comers	25k	Pumitamig3	Phase 3 in China	2026
	1L TNBC – CPS < 10	15k	Pumitamig3	ROSETTA Breast-01	2029
	2L+ HR+ BC – HER2-low	50k	T-Pam5	DYNASTY Breast-02	2026
Genitourinary	1L RCC	25k	Pumitamig3	ROSETTA RCC-2087	2030+
	1L CRPC	100k	BNT324/ DB-13115	BNT324-03	2029
	Adj. MIUC	50k	Autogene cevumeran6	IMCODE004	2029
Gastrointestinal	1L mMSS-CRC	220k	Pumitamig3	ROSETTA CRC-203	2030+
	1L Gastric– HER2-neg, PD-L1+	35k	Pumitamig3	ROSETTA Gastric-204	2030+
	1L HCC	25k	Pumitamig3	ROSETTA HCC-2067	2030+
	Adj. CRC – ctDNA+	70k	Autogene cevumeran6	BNT122-01	2026
	Adj. PDAC	40k	Autogene cevumeran6	IMCODE003	2029
Gynecologic	2L+ Endometrial– HER2-expressing	30k	T-Pam5	Single-Arm Phase 2	2026
			T-Pam5	Fern-EC-014	2028
Additional Tumors	1L HNSCC	150k	Pumitamig3	ROSETTA HNSCC-205	2030+
	1L HNSCC – PDL1 CPS ≥ 1, HPV16+	50k	BNT113	AHEAD-MERIT	2026

1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients) in 2030 in the G7 markets derived from Oracle CancerMPact as of Dec 2025; incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech’s and its collaborators’ product candidates, if approved; 2. Expected data readouts may be from interim or final analyses, and in some cases may not translate into commercial launches; partnered with 3. BMS; 4. OncoC4; 5. DualityBio; 6. Genentech, a member of the Roche group; 7. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030.

Abbreviations: CPS = combined positive score; BC = breast cancer; MIUC = muscle-invasive urothelial carcinoma; PDAC = pancreatic ductal adenocarcinoma.

Financial Position and Outlook

BioNTech maintained a strong financial position throughout 2025, driven by its revenue-generating COVID-19 vaccine business and strategic partnership with BMS. BioNTech held approximately €17.2 billion in cash, cash equivalents and security investments² as of December 31, 2025. In November 2025, the Company increased its 2025 revenue guidance to a range of €2.6-2.8 billion, and lowered expense guidance ranges for R&D, SG&A and capital expenditures.

In 2026, BioNTech anticipates a modest decline in Comirnaty revenues compared to 2025, reflecting COVID-19 vaccine market dynamics, which are influenced by various factors, including but not limited to changing vaccine recommendations, specifically in the United States, and the continued transition from multi-year contracts to private markets in different geographies. BioNTech does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026. Per the outlined partnership terms, revenues to BioNTech from the collaboration with BMS in 2026 are expected to be broadly in line with 2025.

Upcoming Investor and Analyst Events

• Full Year and Fourth Quarter 2025 Financial Results: March 10, 2026
• Annual General Meeting: May 15, 2026

About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes immunomodulators, targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies, and mRNA cancer immunotherapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s collaborations, including its collaboration with Bristol Myers Squibb (BMS); BioNTech and its collaborators’ ability to successfully co-develop and co-commercialize their candidates, if approved; the rate and degree of market acceptance of BioNTech and its collaborators’ product candidates, if approved; the initiation, timing, progress, and results of BioNTech’s research and development programs, including BioNTech’s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential indications in which product candidates may be approved, if at all; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries and regions; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended September 30, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

¹ Preliminary, unaudited figure; consists of cash and cash equivalents plus security investments, as of December 31, 2025. 
² Preliminary, unaudited figure; consists of cash, cash equivalents and security investments, as of December 31, 2025.

 

FAQ

What 2026 oncology milestones did BioNTech (BNTX) announce?

BioNTech expects 15 Phase 3 trials by year-end 2026 and seven late-stage readouts during 2026.

How much cash did BioNTech report on Dec 31, 2025 for BNTX?

BioNTech reported approximately €17.2 billion in cash, cash equivalents and security investments.

Will BioNTech (BNTX) generate oncology revenues in 2026?

No; the company does not currently anticipate recognition of oncology product revenues in 2026.

What 2025 financial guidance did BioNTech (BNTX) provide?

BioNTech increased 2025 revenue guidance to €2.6–2.8 billion and lowered expense guidance ranges.

When and where is BioNTech (BNTX) presenting its J.P. Morgan update?

The presentation is webcast on Jan 13, 2026; slide deck and a 30-day replay will be available on the company website.